Orphazyme to Prepare for Filing of Arimoclomol in US for Niemann-Pick Disease Type C (NPC)

Copenhagen, July 21, 2019– Orphazyme A/S (ticker: ORPHA.CO), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announces that it has had a positive meeting with the FDA and...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials